Table 5 Studies addressing prevalence and clinical association of aPS/PT antibodies
Reference | Studied population | N | Prevalence of anti-PS/PT | Clinical association |
|---|---|---|---|---|
Galli et al. [33] | aPL-positive subjects | 59 | 90% | No association with thrombosis |
IgG 75% | ||||
IgM 66% | ||||
Atsumi et al. [37] | Patients with autoimmune diseases | 265 | IgG: PAPS 19%; SLE APS 63%; SLE-no APS 13% | Association with APS |
IgM: PAPS 10%; SLE APS 29%; SLE-no APS 4% | ||||
Nojima et al. [62] | SLE patients | 126 | 38.1% | No association with stroke |
Bertolaccini et al. [47] | SLE patients | 212 | 31% | No association with thrombosis |
IgG-only 16% | ||||
IgM-only 6% | ||||
Tsutumi et al. [51] | SLE patients | 139 | 21% | Association with thrombosis |
Nojima et al. [52] | SLE patients | 175 | 43.4% | Association with thrombosis |
Bardin et al. [55] | APS patients | 62 | 55% | NI |
Jakowski [56] | APS patients | 58 | 44% | No association with pregnancy loss |
Women with RPL | 66 | 1% | ||
Atsumi et al. [63] | Patients with autoimmune diseases | 441 | 18.3% | Association with APS |
PAPS | 84 | 39% | ||
SLE-APS | 68 | 47% | ||
SLE-no APS | 136 | 10% | ||
Rheumatoid arthritis | 46 | 0 | ||
Sjogren syndrome | 36 | 0 | ||
Other | 71 | 4% | ||
Žigon et al. [64] | APS patients | 100 | 59% | NI |
Vlagea et al. [65] | PAPS patients | 98 | 51%, IgG 35.7%, IgM 32.6% | Association with venous thrombosis and obstetric morbidity |
SAPS patients | 45 | 53.3%, IgG 40%, IgM 31.1% | ||
aPL-positive subjects | 57 | 38.6%, IgG 21.1%, IgM 26.3% | ||
Pregnolato et al. [26] | APS patients | 80 | 81.3% | Association with venous thrombosis (IgG only) |